塞来昔布联合玻璃酸钠治疗膝骨关节病疗效探究
The Effect of Celecoxib Combined with Sodium Hyaluronate in the Treatment of Knee Osteoarthropathy

目的：通过比较塞来昔布、塞来昔布联合玻璃酸钠治疗膝骨关节病的疗效，为临床治疗提供参考。方法：选取2019年1月至6月于我院接受保守治疗的膝骨关节病患者100例，按照随机数法分为单纯口服塞来昔布组和塞来昔布联合玻璃酸钠组各50例，塞来昔布200 mg，2次/日，连续口服8周；玻璃酸钠注射液2.5 ml，1次/周，5周为1疗程。随访患者接受治疗前、治疗后1个月、3个月、6个月的VAS疼痛评分、Lysholm评分及WOMAC评分。结果：两组患者治疗前VAS疼痛评分、Lysholm评分及WOMAC评分无明显差异(P > 0.05)；治疗后1个月、3个月、6个月的VAS疼痛评分、Lysholm评分联合组均明显优于塞来昔布组，1个月、3个月的WOMAC评分联合组优于塞来昔布组(P < 0.05)，6个月时两组差异无统计学意义(P > 0.05)。结论：单纯口服塞来昔布、联合治疗均可取得良好的效果，但塞来昔布联合玻璃酸钠效果更佳，建议临床使用。
Objective: To provide reference for clinical treatment by comparing the efficacy of celecoxib and celecoxib combined with sodium hyaluronate in the treatment of knee osteoarthritis. Method: A total of 100 patients with knee osteoarthritis who received conservative treatment in our hospital from January to June 2019 were randomly divided into oral celecoxib group (50) and celecoxib combined with sodium hyaluronate group (50); for example, celecoxib 200 mg, twice a day, orally for 8 consecutive weeks; sodium hyaluronate injection 2.5 ml, once a week, 5 weeks as a course of treatment. The VAS pain score, Lysholm score and WOMAC score were followed up before treatment, 1 month, 3 months, and 6 months after treatment. Results: There was no significant difference in VAS pain score, Lysholm score and WOMAC score between the two groups before treatment (P > 0.05); the VAS pain score and Lysholm score in combined group were significantly better at 1 month, 3 months, and 6 months after treatment. In the celecoxib group, the combined WOMAC score of 1 month and 3 months was better than that of the celecoxib group (P < 0.05), and there was no significant difference between the two groups at 6 months (P > 0.05). Conclusion: Simple oral celecoxib and combination therapy can achieve good results, but the effect of celecoxib combined with sodium hyaluronate is better, and clinical use is recommended.